Hong Kong-listed precision-medicine firm Mega Genomics announced a repurchase of 93,200 ordinary shares on 7 July 2026, increasing its treasury stock to 119,600 shares.

The on-market transaction, executed under the company’s 21 May 2026 share-buyback mandate, was completed at prices ranging between HKD 6.73 and HKD 7.43 per share, with a volume-weighted average cost of HKD 7.42. Aggregate consideration totalled approximately HKD 0.69 million.

Following the buyback, Mega Genomics’ issued share capital (excluding treasury shares) fell by 0.0416% to 224.18 million shares, while total issued shares remained unchanged at 224.30 million shares. The newly repurchased stock is being held in treasury, with no shares cancelled to date.

Since obtaining the current mandate—authorising repurchases of up to 22.43 million shares—the company has bought back 119,600 shares, equivalent to 0.0533% of the share base on the mandate’s approval date. In line with Hong Kong Stock Exchange rules, Mega Genomics is restricted from issuing new shares or disposing of treasury shares until 7 August 2026.

The board has confirmed that the repurchase complied with all applicable listing rules and regulatory requirements, and that the requisite funds have been fully settled.